Camrelizumab Combined With Apatinib Mesylate for Perioperative Treatment of Resectable Hepatocellular Carcinoma
Status:
Recruiting
Trial end date:
2026-03-01
Target enrollment:
Participant gender:
Summary
Hepatocellular carcinoma (HCC) is the most common primary liver cancer. Hepatectomy is a
curable and effective method. However, the recurrence rate is as high as 50%~70% in 5 years
after surgery. Perioperative treatment with immunotherapy combined with target therapy is
expected to improve the patient's prognosis. This study aims to evaluate the efficacy, safety
and tolerability of camrelizumab combined with apatinib mesylate in the perioperative period
of resectable hepatocellular carcinoma. The primary purpose of this study is to evaluate the
rate of subjects with major pathological response and 3-year event-free survival (EFS) of
camrelizumab combined with apatinib mesylate in the perioperative period of hepatocellular
carcinoma (CNLC Ib-IIIa). The secondary research purpose is to evaluate the R0 resection
rate, the rate of subjects with pathological complete response, EFS, overall survival and
disease-free survival of camrelizumab combined with apatinib mesylate in the perioperative
period of resectable hepatocellular carcinoma. The safety and tolerability is also evaluated.